U.S. markets closed

MediciNova, Inc. (MNOV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.7600-0.0700 (-1.83%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close3.8300
Open3.8000
Bid3.7000 x 900
Ask3.8600 x 900
Day's Range3.7200 - 3.8550
52 Week Range3.7100 - 13.2500
Volume372,217
Avg. Volume301,582
Market Cap183.37M
Beta (5Y Monthly)1.38
PE Ratio (TTM)N/A
EPS (TTM)-0.2500
Earnings DateJul 26, 2021 - Jul 30, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Should I Buy MediciNova, Inc. (MNOV)?
    Insider Monkey

    Should I Buy MediciNova, Inc. (MNOV)?

    The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F filings […]

  • MediciNova to Participate in Maxim Group LLC Fireside Chat
    GlobeNewswire

    MediciNova to Participate in Maxim Group LLC Fireside Chat

    LA JOLLA, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will participate in a fireside chat hosted by Maxim Group LLC Analyst Jason McCarthy, Ph.D., Senior Managing Director, Biotechnolog

  • MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
    GlobeNewswire

    MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

    LA JOLLA, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has initiated a sheep study to investigate MN-166 (ibudilast) in an ovine model of chlorine-induced acute lung injury. Following treatment of the sheep with MN-166 (ibudilast) or control, the study will evaluate pulmonary function, lung injury and edema formation